[go: up one dir, main page]

WO2012039691A2 - Effet synergique - Google Patents

Effet synergique Download PDF

Info

Publication number
WO2012039691A2
WO2012039691A2 PCT/TR2011/000213 TR2011000213W WO2012039691A2 WO 2012039691 A2 WO2012039691 A2 WO 2012039691A2 TR 2011000213 W TR2011000213 W TR 2011000213W WO 2012039691 A2 WO2012039691 A2 WO 2012039691A2
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
composition according
sodium
starch
generation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2011/000213
Other languages
English (en)
Other versions
WO2012039691A3 (fr
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2012039691A2 publication Critical patent/WO2012039691A2/fr
Publication of WO2012039691A3 publication Critical patent/WO2012039691A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Definitions

  • the present invention relates to use of N- Acetylcysteine which is a mucolytic agent and a non-sedating, third generation HI receptor antagonist in combination; and pharmaceutical compositions comprising said combination which can be used in respiratory tract diseases.
  • the present invention provides an effective combination that is indicated in acute and chronic bronchopulmonary diseases, bronchitis, rhinitis, allergic respiratory problems, expectoration and reduction of phlegm.
  • Desloratadine which has the chemical name 8-chloro-6,l l-dihydro-l l-(4-piperidinyl)-5H- benzo[5,6]cyclohepta[l,2-b]pyridine(Formw/a I), is a long-acting, non-sedative antihistamine.
  • Desloratadine was first disclosed in the patent numbered US 4,659,716. This patent comprises processes for preparation of desloratadine; pharmaceutical compositions comprising desloratadine; and non-sedative antihistaminic activity of desloratadine.
  • Desloratadine is a non-sedative, third generation HI antagonist which does not cause sedation. It competes with histamine for HI receptors; and blocks binding of histamine to HI receptors. Desloratadine which is an active metabolite of loratadine is an oral HI antagonist.
  • Levocetirizine chemical name of which is 2-[2-[4-[(R)-(4-chlorophenyl)-phenyl-methyl] piperazine-l-yl]ethoxy] acetic acid ⁇ Formula II) is a non-sedative, long acting antihistamine.
  • Cetirizine was first disclosed in the patent numbered EP 0058146.
  • the patent numbered GB 2225321 on the preparation process of levocetirizine
  • the patent numbered WO 9406429 on the use of levocetirizine in the treatment of allergic diseases.
  • Levocetirizine an R-enantiomer of cetirizine
  • HI receptor antagonist a strong, piperazine derivative, HI receptor antagonist.
  • Levocetirizine is a new antihistaminic that binds to HI receptors with high affinity, even two times higher affinity than cetirizine. Levocetirizine inhibits the binding of histamine to HI receptors.
  • allergic respiratory tract problems such as allergic rhinitis, allergic sinusitis, allergic bronchitis, allergic bronchopulmonary diseases having symptoms of sneeze, nasal flow, itching, nasal obstruction, itching, lacrimation and redness on eyes, itchy palate and coughing have been observed.
  • allergic bronchopulmonary diseases expectoration and/or phlegm occurs irritating patients, preventing regular breathing and causing cough.
  • NAC ⁇ Formula III is an N-acetylated derivative of L-cysteine and an agent used as mucolytic.
  • NAC breaks disulphide bonds in mucoproteins which are located in the bronchus secretory. Thus, volume of mucus secretion in the pulmonary is reduced.
  • N-Acetylcysteine which has the chemical name N-acetyl-L- cysteine, is described in the patent numbered US 3, 184,505 in detail.
  • the inventors have surprisingly found that a more effective composition than expected and a more significant therapeutic benefit are obtained due to the synergic effect between a third generation HI antagonist and N- Acetylcysteine as a mucolytic agent.
  • the present invention is related to use of NAC in combination with a third generation HI antagonist.
  • the invention provides a treatment method comprising use of the synergistically effective combination of NAC and a third generation HI antagonist in respiratory tract diseases.
  • the pharmaceutical combination of the present invention comprises;
  • the third generation receptor antagonist is selected from a group comprising levocetirizine, desloratidine or their combination.
  • the combination of the present invention comprises use of NAC as a mucolytic agent in combination with levocetirizine, desloratidine or a combination thereof.
  • Treatments in which the combination of the present invention is used comprises administration of a third generation HI receptor antagonist and N- Acetylcystein in therapeutically effective amounts and activity of said combination is synergistic against the bronchopulmonary diseases and allergic respiratory tract diseases.
  • the active agents of the said combination can be in free form or in the form of pharmaceutically acceptable salts, enantiomers, racemates, solvates, hydrates, different polymorphic forms and amorphous form thereof.
  • the composition of the present invention can be used simultaneously, sequentially or separately for reducing the symptoms of respiratory tract diseases or slowing the progression of the diseases.
  • the pharmaceutical composition of the present invention is indicated particularly in acute and chronic bronchopulmonary diseases; seasonal and/or perennial rhinitis, sinusitis, bronchitis, allergic and/or inflammatory diseases of upper and lower respiratory tracts and allergic respiratory problems.
  • combinations of the present invention can be prepared as medicament compositions so as to be administered to mammals including human particularly for the treatment of acute and chronic bronchopulmonary diseases; seasonal and/or perennial rhinitis, sinusitis, bronchitis, allergic and/or inflammatory diseases of upper and lower respiratory tracts and allergic respiratory problems.
  • the present invention relates to a pharmaceutical composition which will be used for production of an effective medicament so as to be utilized in the treatment of respiratory tract diseases wherein said composition is characterized by comprising NAC and a third generation HI receptor antagonist as active agents.
  • it is targeted to reduce symptoms of respiratory tract diseases, slow the progression of the diseases and treat the diseases by means of pharmaceutical compositions in which effective amounts of NAC and effective amounts of a third generation HI receptor antagonist and sufficient amounts of excipient/excipients are combined.
  • the phrase “reduction of the symptoms” refers to reducing the number of the symptoms observed in people who are diagnosed with said disease by means of administering the pharmaceutical composition comprising the combination of NAC and a third generation HI receptor antagonist to diagnosed people.
  • the phrase “slowing the progression of the disease” refers to administration of the pharmaceutical composition comprising the combination of NAC and a third generation HI receptor antagonist to people who are diagnosed with said disease and/or in the first phase of said disease.
  • treatment of the disease refers to removing present problems related to the disease by administering the pharmaceutical composition comprising the combination of NAC and a third generation HI receptor antagonist to people who are diagnosed with said disease and in any phases of the disease.
  • composition of the present invention can be administered simultaneously, sequentially or separately so as to be used in the treatment of respiratory tract diseases.
  • the active agents in the composition of the present invention can be formulated separately in order to be used in a kit form where they are placed together.
  • the amount of active agent in the composition of the present invention varies in the range of 0.5% to 95%, preferably in the range of 1% to 90% by weight in proportion to total amount of the pharmaceutical composition.
  • dosage of the active agents in the pharmaceutical composition can vary according to the route of administration, the patent's age and state of health.
  • the ratio of NAC and a third generation HI receptor antagonist by weight in the oral composition varies in range of 1 :0,05 to 1:5.
  • the ratio of the third generation HI receptor antagonist to the total amount of substances in the composition varies in the range of 1-50% by weight and the ratio of N- Acetylcysteine to the total amount of substances in the composition varies in the range of 1-90% by weight.
  • the pharmaceutical composition of the present invention can comprise a third generation HI receptor antagonist in the range of 0,1 mg to 50 mg and NAC in the range of 10 mg to 2000 mg in one dose.
  • the pharmaceutical composition of the present invention can be prepared as applicable by the oral route.
  • compositions of the present invention comprise oral dosage forms and pharmaceutical formulations comprising the active agents alone or together with pharmaceutically acceptable excipients.
  • the oral dosage forms in which said composition will be formulated can be solid forms such as tablet; capsule; enterically coated or modified release tablet; prolonged release tablet; delayed release tablet; fast soluble tablet; effervescent tablet; effervescent granule; fast soluble powder mixture; water soluble powder, tablet, or granule; granule; pellet; minitablet; microtablet; granule capsule, pellet capsule, minitablet capsule, microtablet capsule; or dry powder mixture for syrup preparation; dragee; orally disintegrated tablets; film tablet or solid forms comprising their combination, or in liquid forms such as suspensions.
  • the pharmaceutical composition of the present invention can be formulated preferably in the form of water-soluble powder, tablet or granule.
  • the absorption of the pharmaceutical formulation from the gastrointestinal tract increases when it is formulated this way.
  • Effervescent formulations according to the present invention dissolve completely in water at the room temperature in less than 5 minutes.
  • degradation is observed in the combination of the present invention due to the fact that third generation HI receptor antagonist agents are unstable; thus it is hard to formulate them. Therefore, ratio of the third generation HI receptor antagonist to binder in the composition of the present invention is in the range of 1 :20 to 1 :45 and the amount of NAC is in the range of 1-50% by weight of the total weight.
  • using polyvinylpyrrolidone as binder in the pharmaceutical composition of the present invention provides a more stable pharmaceutical composition.
  • the combination of the present invention is produced from NAC, a third generation HI receptor antagonist, and preferably a pharmaceutically acceptable excipient by conventional techniques.
  • compositions of the present invention can also be used in addition to the active agents used in the formulation of the present invention.
  • excipients can be selected from additives such as pharmaceutically acceptable binder, sweetener, lubricant, flavoring agent, diluent, disintegrant, surfactant and glidant.
  • binders can be selected from, but not limited to, a group comprising starches (such as potato starch, corn starch, wheat starch); sugars such as sucrose, glucose, dextrose, lactose, maltodextrin; natural and synthetic gums (such as acacia); gelatin; cellulose derivatives (such as microcrystalline cellulose, HPC, HEC, HPMC, carboxymethyl cellulose, methyl cellulose, ethyl cellulose); polyvinylpyrrolidone (PVP), polyethylene glycol (PEG); waxes; calcium carbonate; calcium phosphate; alcohols (such as sorbitol, xylitol, mannitol) and water.
  • starches such as potato starch, corn starch, wheat starch
  • sugars such as sucrose, glucose, dextrose, lactose, maltodextrin
  • natural and synthetic gums such as acacia
  • gelatin such as cellulose derivatives (such as microcrystalline cellulose, HP
  • Pharmaceutically acceptable sweeteners can be selected from, but not limited to, a group comprising sucralose, sucrose, fructose, glucose, galactose, xylose, dextrose, levulose, lactose, maltose, maltodextrin, mannitol, maltitol, maltol, sorbitol, xylitol, erythritol, lactitol, isomalt, corn syrup, saccharine, saccharine salts, acesulfame potassium, aspartam, D-tryptophane, monoammonium glycyrrhizinate, neohesperidine dihyrochalcon, thaumatin, neotam, alitam, stevioside, cyclamates and sodium chloride.
  • Pharmaceutically acceptable lubricants can be selected from, but not limited to, a group comprising metallic stearates (such as magnesium stearate, calcium stearate, aluminium stearate), fatty acid esters (such as sodium stearyl fumarate), fatty acids (such as. stearic acid), fatty alcohols, glyceryl behenate, mineral oil, paraffins, hydrogenated vegetable oil, leucine, polyethylene glycols (PEG), metallic lauryl sulphates (such as sodium lauryl sulphate, magnesium lauryl sulphate), sodium chloride, sodium benzoate, sodium acetate and talc.
  • metallic stearates such as magnesium stearate, calcium stearate, aluminium stearate
  • fatty acid esters such as sodium stearyl fumarate
  • fatty acids such as. stearic acid
  • fatty alcohols such as sodium stearic acid
  • fatty alcohols such as sodium stearic acid
  • Pharmaceutically acceptable diluents can be selected from, but not limited to, a group comprising lactose, microcrystalline cellulose, starch, pregelatinized starch, modified starch, calcium phosphate (dibasic and/or tribasic), calcium sulphate trihydrate, calcium sulphate dihydrate, calcium carbonate, kaolin, lactilol, cellulose powder, dextrose, dextrates, dextrine, sucrose, maltose, fructose, mannitol, sorbitol and xylitol.
  • a group comprising lactose, microcrystalline cellulose, starch, pregelatinized starch, modified starch, calcium phosphate (dibasic and/or tribasic), calcium sulphate trihydrate, calcium sulphate dihydrate, calcium carbonate, kaolin, lactilol, cellulose powder, dextrose, dextrates, dextrine, sucrose, maltose, fructose,
  • Pharmaceutically acceptable disintegrants can be selected from, but not limited to, a group comprising starches (corn starch, potato starch); sodium starch glycolate; pregelatinized starch; cellulose derivatives (such as croscarmellose sodium or microcrystalline cellulose); polyvinylpyrrolidone (PVP); crospovidone; alginic acid; sodium alginate; clays (such as xanthan gum or Veegum); ion exchange resins and effervescent systems (alkaline or alkaline earth metal carbonates[sodium carbonate, sodium hydrogen carbonate, potassium carbonate, potassium hydrogen carbonate, calcium carbonate]; water soluble polybasic organic acids or their salts such as sodium hydrogen sulphate, potassium hydrogen sulphate, sodium dihydrogen phosphate, succinic acid, tartaric acid, adipic acid, citric acid, etc).
  • starches corn starch, potato starch
  • sodium starch glycolate such as croscarmellose sodium or microcrystalline cellulose
  • glidants can be selected from, but not limited to, a group comprising silicone dioxide, magnesium trisilicate, cellulose powder, starch, talc, tribasic calcium phosphate, metallic stearates, calcium silicate and metallic lauryl sulphates.
  • Pharmaceutically acceptable surfactants can be selected from, but not limited to, a group comprising polyoxyethylene-sorbitan-fatty acid esters (polysorbates), sodium lauryl sulphate, sodium stearyl fumarate, polyoxyethylene alkyl ethers, sorbitan fatty acid esters, polyethylene glycols (PEG), polyoxyethylene castor oil derivatives, docusate sodium, quaternary ammonium compounds, aminoacids such as L-leucine, sugar esters of fatty acids and glycerides of fatty acids.
  • PEG polyethylene glycols
  • other pharmaceutically acceptable excipients such as solubility modulators, effervescent couple, coloring agents and coating agents can be used in the formulation.
  • the active agents N-Acetylcysteine and desloratadine are prepared as a pharmaceutical composition by the conventional techniques in the prior art.
  • the homogenous mixture obtained thereafter is dried and shaped as required.
  • the active agents N-Acetylcysteine and levocetirizine are prepared as a pharmaceutical composition by the conventional techniques in the prior art.
  • the homogenous mixture obtained thereafter is dried and shaped as required.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne l'utilisation, en combinaison, de N-acétylcystéine qui est un agent mucolytique et un antagoniste de troisième génération du récepteur H1, non sédatif ; et des compositions pharmaceutiques comprenant ladite combinaison qui peuvent être utilisées pour des maladies du tractus respiratoire.
PCT/TR2011/000213 2010-09-20 2011-09-20 Effet synergique Ceased WO2012039691A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/07652 2010-09-20
TR2010/07652A TR201007652A2 (tr) 2010-09-20 2010-09-20 Sinerjik etki.

Publications (2)

Publication Number Publication Date
WO2012039691A2 true WO2012039691A2 (fr) 2012-03-29
WO2012039691A3 WO2012039691A3 (fr) 2012-05-18

Family

ID=45034153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000213 Ceased WO2012039691A2 (fr) 2010-09-20 2011-09-20 Effet synergique

Country Status (2)

Country Link
TR (1) TR201007652A2 (fr)
WO (1) WO2012039691A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106109422A (zh) * 2016-07-28 2016-11-16 北京万全德众医药生物技术有限公司 盐酸左西替利嗪泡腾颗粒及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3184505A (en) 1962-06-18 1965-05-18 Mead Johnson & Co Process for the n-monoacylation of cysteine
EP0058146A1 (fr) 1981-02-06 1982-08-18 U C B, S.A. Nouveaux acides 2-(4-(diphénylméthyl)-1-pipérazinyl)-acétiques et leurs amides, leurs procédés de préparation et compositions thérapeutiques
US4659716A (en) 1984-02-15 1987-04-21 Schering Corporation Antihistaminic 8-(halo)-substituted 6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridines
GB2225321A (en) 1988-11-23 1990-05-30 Ucb Sa Process for preparation of a 1-piperazine-ethoxyacetic acid
WO1994006429A1 (fr) 1992-09-24 1994-03-31 Sepracor, Inc. Compositions pour traiter des affections allergiques a l'aide de (-) cetirizine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085148A2 (fr) * 2000-05-05 2001-11-15 Aventis Pharmaceuticals Inc. Procede d'emballage d'hydrochlorures de pseudoephedrine et de fexofenadine
WO2005065047A2 (fr) * 2003-12-23 2005-07-21 Sun Pharmaceutical Industries Limited Composition orale stable
US20080139654A1 (en) * 2006-12-09 2008-06-12 Eric Mott Soderling Acetaminophen compositions having minimized side effects including reduced hepatotoxicity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3184505A (en) 1962-06-18 1965-05-18 Mead Johnson & Co Process for the n-monoacylation of cysteine
EP0058146A1 (fr) 1981-02-06 1982-08-18 U C B, S.A. Nouveaux acides 2-(4-(diphénylméthyl)-1-pipérazinyl)-acétiques et leurs amides, leurs procédés de préparation et compositions thérapeutiques
US4659716A (en) 1984-02-15 1987-04-21 Schering Corporation Antihistaminic 8-(halo)-substituted 6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridines
GB2225321A (en) 1988-11-23 1990-05-30 Ucb Sa Process for preparation of a 1-piperazine-ethoxyacetic acid
WO1994006429A1 (fr) 1992-09-24 1994-03-31 Sepracor, Inc. Compositions pour traiter des affections allergiques a l'aide de (-) cetirizine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106109422A (zh) * 2016-07-28 2016-11-16 北京万全德众医药生物技术有限公司 盐酸左西替利嗪泡腾颗粒及其制备方法

Also Published As

Publication number Publication date
TR201007652A2 (tr) 2012-04-24
WO2012039691A3 (fr) 2012-05-18

Similar Documents

Publication Publication Date Title
AU2018246214B2 (en) Niraparib compositions
US20250228833A1 (en) Methods and compositions for treating agitation
WO2010107404A1 (fr) Combinaisons pharmaceutiques stables
EP2167065A1 (fr) Thérapie par combinaison pour la dépression
JP2014520842A (ja) モンテルカストおよびリボセチリジン配合のカプセル製剤
EP2331079A2 (fr) Préparation pharmaceutique
WO2012064301A2 (fr) Formulations de comprimés aux propriétés physiques améliorées
JP7243876B2 (ja) 固形製剤
US10426724B2 (en) Antihistamine compositions, combinations, and use thereof
JP5362151B2 (ja) Ｐｇｄ２拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬
CN104771390A (zh) 牡荆素的用途
EP2571499A1 (fr) Composition pharmaceutique contenant de la n- acétylcystéine et une xanthine
WO2014035355A1 (fr) Combinaisons pharmaceutiques comprenant un agent actif dérivé de la quinone
WO2012039691A2 (fr) Effet synergique
CN104771387B (zh) 三七素的用途
PT2106258E (pt) Ibuprofeno contra a tosse
EP2571485B1 (fr) Formulations antihistaminiques effervescentes
EP3238714A1 (fr) Formulations à libération prolongée de flurbiprofène et de tramadol
US9265757B2 (en) Methods of administering antihistamines
CN104771408A (zh) 三七皂苷Ft1的用途
WO2024230943A1 (fr) Linaprazan glurate pour le traitement du reflux gastro-œsophagien pathologique (gerd)
WO2022090482A1 (fr) Compositions pharmaceutiques comprenant du 15-hetre et leurs méthodes d'utilisation
US20110160213A1 (en) Pharmaceutical compositions for the treatment of inflammatory and allergic disorders
TR201612545A1 (tr) Oral farmasöti̇k terki̇pler
EP3095466A1 (fr) Formulations pharmaceutiques avec solubilité et stabilité améliorée

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11787952

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11787952

Country of ref document: EP

Kind code of ref document: A2